John Hemphill, MD
Interventional Cardiology · Chattanooga, TNNPI 1912188897
Payments from drug & device makers
Across 139 payments — averaging $90.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Axsome Therapeutics, Inc.$8K
- Abiomed$824
- Shockwave Medical, Inc$502
- Boston Scientific$373
- Medtronic$371
- Abbott$325
- plus $2K from 28 others
What the payments were for
- Consulting fees$7,96963%
- Food & beverage$4,59937%
- Education$140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Axsome Therapeutics, Inc. | 1 | $7,969 |
| Abiomed | 11 | $824 |
| Shockwave Medical, Inc | 3 | $502 |
| Boston Scientific | 7 | $373 |
| Medtronic(2 entities) | 29 | $371 |
| Abbott | 4 | $325 |
| AstraZeneca(2 entities) | 14 | $253 |
| Novartis | 10 | $252 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $220 |
| Getinge USA Sales, LLC | 3 | $207 |
| Heartflow, Inc. | 1 | $165 |
| Teleflex LLC | 5 | $158 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $149 |
| Teva Pharmaceuticals USA, Inc. | 6 | $98 |
| Johnson & Johnson | 3 | $70 |
| Biogen | 4 | $68 |
| AbbVie(2 entities) | 5 | $59 |
| Asahi Intecc USA, Inc. | 1 | $58 |
| Pfizer | 2 | $55 |
| Amarin Pharma, Inc. | 1 | $48 |
| Terumo Medical Corporation | 2 | $45 |
| E.r. Squibb & Sons, L.L.C. | 2 | $38 |
| Averitas Pharma Inc. | 1 | $36 |
| Chiesi USA, Inc. | 2 | $33 |
| Biotronik Inc. | 1 | $31 |
| Amgen | 2 | $30 |
| Kiniksa Pharmaceuticals, Ltd. | 1 | $29 |
| Cardiovascular Systems Inc. | 2 | $25 |
| Boehringer Ingelheim | 1 | $23 |
| Kestra Medical Technology Services, Inc. | 1 | $15 |
| Otsuka America Pharmaceutical, Inc. | 1 | $15 |
| Cordis US CORP. | 1 | $15 |
| Philips North America LLC | 1 | $14 |
| Baylis Medical Company Inc | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$12,582 in reported general payments places this provider in the 55th percentile of 207 interventional cardiology providers in Tennessee.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 645 | $712,932 |
| EntrestoSacubitril/Valsartan | 238 | $278,151 |
| FarxigaDapagliflozin Propanediol | 96 | $119,032 |
| XareltoRivaroxaban | 95 | $110,957 |
| JardianceEmpagliflozin | 85 | $88,727 |
| Repatha SureclickEvolocumab | 43 | $33,625 |
| Valsartan | 304 | $13,921 |
| Dabigatran EtexilateDabigatran Etexilate Mesylate | 40 | $10,328 |
| Atorvastatin Calcium | 511 | $6,949 |
| Metoprolol Succinate | 435 | $6,936 |
| Rosuvastatin Calcium | 525 | $6,633 |
| Carvedilol | 780 | $6,248 |
| Losartan Potassium | 313 | $3,615 |
| Potassium Chloride | 170 | $3,372 |
| ClopidogrelClopidogrel Bisulfate | 257 | $3,129 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $55 | $712,932645 claims |
| NovartisEntresto | $252 | $278,151238 claims |
| AstraZenecaFarxiga | $253 | $119,03296 claims |
| Johnson & JohnsonXarelto | $70 | $110,95795 claims |
| Boehringer IngelheimJardiance | $23 | $88,72785 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 207 interventional cardiology providers in Tennessee.
Other interventional cardiology in Chattanooga
- Matthew WiisanenChattanooga$161K
- Brian NegusChattanooga$104K
- John GoldingChattanooga$92K
- Michael MorseNashville$3.5M
- Charles TreasurePowell$3M
- Colin BarkerNashville$2.1M
- Brian JeffersonNashville$2.1M
- Malcolm FosterKnoxville$1.9M
- Rahul SakhujaKingsport$1.9M
- Kashish GoelNashville$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.